Key regions: South Korea, Japan, Europe, Brazil, United Kingdom
The Other Pharmaceuticals market in Southern Europe is a growing industry that has seen significant developments in recent years.
Customer preferences: Customers in Southern Europe have shown a growing preference for natural and organic products, including in the Other Pharmaceuticals market. This trend towards natural products is driven by a desire for healthier lifestyles and a greater awareness of the potential side effects of traditional pharmaceuticals. Additionally, customers are increasingly looking for products that are sustainably sourced and produced.
Trends in the market: In Spain, the Other Pharmaceuticals market is driven by a growing demand for natural remedies and supplements. This trend is particularly evident in the growing popularity of products containing CBD, which is believed to have a range of health benefits. In Italy, the market is dominated by homeopathic remedies, which are seen as a more natural and holistic approach to healthcare. In Greece, there is a growing demand for products that are derived from traditional Greek herbs and plants, which are believed to have a range of health benefits.
Local special circumstances: One of the key factors driving the growth of the Other Pharmaceuticals market in Southern Europe is the region's rich tradition of natural medicine. Many of the products sold in this market are based on traditional remedies that have been used for centuries. Additionally, Southern Europe has a favorable climate for the cultivation of herbs and plants, which are often used in natural remedies and supplements.
Underlying macroeconomic factors: The growth of the Other Pharmaceuticals market in Southern Europe is also being driven by broader macroeconomic trends. The region has seen a growing interest in health and wellness, as well as a rising demand for natural and organic products. Additionally, the region's aging population has created a growing market for products that can help manage age-related health conditions. Finally, the region's growing middle class is increasingly willing to spend money on health and wellness products, including those in the Other Pharmaceuticals market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
